Glycated haemoglobin – HbA1C, or A1C as it is now being called – should be used to diagnose diabetes, according to a recent recommendation from an international expert committee appointed by the American Diabetes Association, the International Diabetes Federation and the European Association for the Study of Diabetes. We explore the basis for this recommendation, and look at why HbA1C would provide a more accurate measure for diagnosing diabetes than glucose tests and what the change would mean in clinical practice.
Starting on a GLP-1 analogue: Byetta or Victoza
Putting the NHS health check programme into action: hearts, brains and kidneys
The prevention of cardiovascular disease (CVD) is being moved up a gear with the ambitious and wide-reaching NHS Health Check programme. The agenda for this programme has been clearly laid out for us in the Putting Prevention First best practice guidance that was published in April 2009. The “Cog Man” on the cover highlights the close links between the heart, brain, kidneys and diabetes, explaining the comprehensive nature of vascular risk assessment, and this image is going to be seen regularly on national leaflets and posters promoting the programme. This article provides a practical guideline for the primary care team on implementing the Health Check programme, setting out who we should be checking, what we should be checking and how we should act on what we find.
Helping your patients to manage their weight: a behavioural approach
The health risks of obesity are only too obvious but, despite this, its prevalence continues to increase. It is a leading cause of both physical and psychological ill health, and is notoriously difficult to treat. For this reason, the National Institute for Health and Clinical Excellence (NICE) emphasises the importance of preventing obesity and has produced guidelines on the most effective approaches. Many health professionals wish to support their patients with weight loss, but research has shown that they do not always feel well equipped to do this. In this article we review the importance of a behavioural approach in managing overweight and obesity and provide practical advice on how to help overweight patients achieve sustainable behavioural change.
New drugs and where they fit in the treatment algorithm
In May 2009, NICE published recommendations on the use of newer agents for the control of blood glucose in type 2 diabetes. This guideline provides a partial update for NICE Clinical Guideline 66 on the management of type 2 diabetes that was published last year. These newer agents include the dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones (TZDs), the glucagon-like peptide-1 (GLP-1) mimetic exenatide and the long-acting insulin analogues (insulin detemir and insulin glargine).
